The company has entered into an accelerated share repurchase program with the bank to buy back a portion of its common stock.
The BD business, which has annual revenues of about $100 million, offers technical services as well as peptones for cell culture media used in biopharmaceutical applications.
Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions.
The repurchase is part of a commitment announced by the company in July 2016 to return $300 million to shareholders by the end of 2017.
Qiagen plans to return about $250 million to shareholders through a program that combines a direct capital repayment with a reverse stock split.
Revenues rose thank to an increase in the company's human health business, which offset a decline in its environmental health segment.
As of the end of its fiscal third quarter of 2016, Myriad had repurchased more than $1.1 billion of stock since the inception of the buyback program in 2010.
Under the repurchase plan, Thermo Fisher is cleared to buy $1 billion of its common stock in both the open market and through negotiated transactions.
The program will run for two years, and Bruker said that it will repurchase its common stock from time to time in amounts and at prices that it deems appropriate.
The firm also completed the repurchase of $96 million in common shares under a previous share repurchase program.
The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.
In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.
The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.
In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.